Monensin medicated feed as an anticoccidial in young dairy goats
The most common cause of diarrhea in two to seven-month-old dairy goats housed in confined quarters is coccidiosis. Recent trials indicated that monensin, the avian coccidiostatic antibiotic and feedlot cattle growth stimulant, provided protection and some therapeutic effects against coccidiosis in goats. Most goats harbor a few coccidia and, once infected, tend to develop an immunity by 9-12 months of age. The presence of a few oocyst does not always justify treatment and may actually benefit by helping the goat to develop an immunity. Clinical signs of diarrhea and weight loss appear during confined housing. No drugs are specifically approved by the FDA as caprine anticoccidials. The cattle drug monensin, at a concentration of 60 grams per pound of premix, is used at a rate of 20 grams per ton of the goats' alfalfa pellets. This dosage of 22 miligrams per kilo of feed is approximately 1 milligram per kilo of the goat's body weight, depending on feed consumption. Clinical signs were observed and eliminated within 4 weeks of use of the medicated feed, the oocysts gradually dropping to non-detectable numbers. The number of fecal oocyst rose again following withdrawal of the drug, suggesting a more static than cidal action. No palatability problems or toxic effects were attributed to monensin in goats during this trial
| Main Authors: | , , , |
|---|---|
| Format: | Texto biblioteca |
| Language: | eng |
| Published: |
Scottsdale, AZ (EUA)
1982
|
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The most common cause of diarrhea in two to seven-month-old dairy goats housed in confined quarters is coccidiosis. Recent trials indicated that monensin, the avian coccidiostatic antibiotic and feedlot cattle growth stimulant, provided protection and some therapeutic effects against coccidiosis in goats. Most goats harbor a few coccidia and, once infected, tend to develop an immunity by 9-12 months of age. The presence of a few oocyst does not always justify treatment and may actually benefit by helping the goat to develop an immunity. Clinical signs of diarrhea and weight loss appear during confined housing. No drugs are specifically approved by the FDA as caprine anticoccidials. The cattle drug monensin, at a concentration of 60 grams per pound of premix, is used at a rate of 20 grams per ton of the goats' alfalfa pellets. This dosage of 22 miligrams per kilo of feed is approximately 1 milligram per kilo of the goat's body weight, depending on feed consumption. Clinical signs were observed and eliminated within 4 weeks of use of the medicated feed, the oocysts gradually dropping to non-detectable numbers. The number of fecal oocyst rose again following withdrawal of the drug, suggesting a more static than cidal action. No palatability problems or toxic effects were attributed to monensin in goats during this trial |
|---|